Antithymocytes globulins: Time to revisit its use in kidney transplantation?

References

• Rebellato LM, Gross U, Verbanac KM, Thomas JM. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994;57(5):685–694. doi:10.1097/00007890-199403150-00010. PMID:7908150.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991;51(3):669–673. doi:10.1097/00007890-199103000-00024. PMID:2006524.
   PubMed Web of Science ®Google Scholar
• Mohty M. Mechanisms of action of antithymocyte globulin: t-cell depletion and beyond. Leukemia 2007;21(7):1387–1394. doi:10.1038/sj.leu.2404683. PMID:17410187.
   PubMed Web of Science ®Google Scholar
• Popow I, Leitner J, Grabmeier-Pfistershammer K, et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am J Transplant. 2013;13(12):3103–3113. doi:10.1111/ajt.12514. PMID:24168235.
   PubMed Web of Science ®Google Scholar
• Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol. 2012;12(6):417–430. doi:10.1038/nri3227. PMID:22627860.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67:1011–1018. doi:10.1097/00007890-199904150-00013. PMID:10221486.
   PubMed Web of Science ®Google Scholar
• Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003;76:798–802. doi:10.1097/01.TP.0000081042.67285.91. PMID:14501856.
   PubMed Web of Science ®Google Scholar
• Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002;73:473–475. doi:10.1097/00007890-200202150-00025. PMID:11884948.
   PubMed Web of Science ®Google Scholar
• Baron F, Mohty M, Blaise D, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working party of the European Society for blood and Marrow transplantation. Haematologica 2017;102:224–234.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Courivaud C, Bamoulid J, et al. Prolonged CD4 T cell lymphopenia increases morbidity and mortality after renal transplantation. J Am Soc Nephrol. 2010;21(5):868–875. doi:10.1681/ASN.2009090976. PMID:20203160.
   PubMed Web of Science ®Google Scholar
• Crepin T, Carron C, Roubiou C, et al. ATG-induced accelerated immune senescence: clinical implications in renal transplant recipients. Am J Transplant. 2015;15(4):1028–1038. doi:10.1111/ajt.13092. PMID:25758660.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Carron PL, Motte G, et al. Lymphocyte subsets and assessment of cancer risk in renal transplant recipients. Transpl Int. 2002;15(8):393–396. doi:10.1111/j.1432-2277.2002.tb00187.x. PMID:12221457.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Challier B, Saas P, Tiberghien P, Chalopin JM. CD4 cell lymphopenia and atherosclerosis in renal transplant recipients. J Am Soc Nephrol. 2003;14(3):767–772. doi:10.1097/01.ASN.0000048718.43419.44. PMID:12595514.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bamoulid J, Courivaud C, et al. Thymic function, anti-thymocytes globulins, and cancer after renal transplantation. Transpl Immunol. 2011;25(1):56–60. doi:10.1016/j.trim.2011.05.003. PMID:21620972.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Courivaud C, Bamoulid J, et al. Polyclonal antithymocyte globulin and cardiovascular disease in kidney transplant recipients. J Am Soc Nephrol. 2014;25(6):1349–1356. doi:10.1681/ASN.2013060663. PMID:24511120.
   PubMed Web of Science ®Google Scholar
• Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45(1):29–32. PMID:8616954.
   PubMed Web of Science ®Google Scholar
• Waller EK, Langston AA, Lonial S, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9(7):460–471. doi:10.1016/S1083-8791(03)00127-7. PMID:12869960.
   PubMed Web of Science ®Google Scholar
• Xie X, Zhao H, Qin D, Qiao X. Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia. Int J Clin Exp Med. 2015;8(3):4349–4355. PMID:26064352.
   PubMed Web of Science ®Google Scholar
• Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Population pharmacokinetic modeling of Thymoglobulin((R)) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2015;54(4):435–446. doi:10.1007/s40262-014-0214-6. PMID:25466602.
   PubMed Web of Science ®Google Scholar
• Vacha M, Gommer J, Rege A, Sanoff S, Sudan D, Harris M. Effects of ideal versus total body weight dosage of rabbit antithymocyte globulin on outcomes of kidney transplant patients with high immunologic risk. Exp Clin Transplant. 2016;14(5):511–517. PMID:26742693.
   PubMed Web of Science ®Google Scholar
• Buchler M, Longuet H, Lemoine R, et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol. 2013;28(2–3):120–126. doi:10.1016/j.trim.2013.03.001. PMID:23507258.
   PubMed Web of Science ®Google Scholar
• Peddi VR, Brvant M, Roy-Chaudhury P, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation 2002;73(9):1514–1518. doi:10.1097/00007890-200205150-00025. PMID:12023634.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Kazory A, Challier B, et al. Long-term toxicity of antithymocyte globulin induction may vary with choice of agent: a single-center retrospective study. Transplantation 2004;77(7):1029–1033. doi:10.1097/01.TP.0000116442.81259.60. PMID:15087766.
   PubMed Web of Science ®Google Scholar
• Paiano S, Roosnek E, Tirefort Y, et al. Comparing two types of rabbit ATG prior to reduced intensity conditioning allogeneic hematopoietic SCT for hematologic malignancies. Bone Marrow Res. 2015;2015:980924. doi:10.1155/2015/980924. PMID:25874131.
   PubMedGoogle Scholar
• Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011;117:6963–6970. doi:10.1182/blood-2011-01-332007. PMID:21464372.
   PubMed Web of Science ®Google Scholar
• Pirofsky B, Ramirez-Mateos JC, August A. “Foreign serum” heterophile antibodies in patients receiving antithymocyte antisera. Blood 1973;42(3):385–393. PMID:4542028.
   PubMed Web of Science ®Google Scholar
• Chou HH, Takematsu H, Diaz S, et al. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci U S A. 1998;95(20):11751–11756. doi:10.1073/pnas.95.20.11751. PMID:9751737.
   PubMed Web of Science ®Google Scholar
• Padler-Karavani V, Yu H, Cao H, et al. Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: potential implications for disease. Glycobiology 2008;18(10):818–830. doi:10.1093/glycob/cwn072. PMID:18669916.
   PubMed Web of Science ®Google Scholar
• Tangvoranuntakul P, Gagneux P, Diaz S, et al. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Natl Acad Sci U S A. 2003;100(21):12045–12050. doi:10.1073/pnas.2131556100. PMID:14523234.
   PubMed Web of Science ®Google Scholar
• Couvrat-Desvergnes G, Salama A, Le Berre L, et al. Rabbit antithymocyte globulin-induced serum sickness disease and human kidney graft survival. J Clin Invest. 2015;125(12):4655–4665. doi:10.1172/JCI82267. PMID:26551683.
   PubMed Web of Science ®Google Scholar
• Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001;71(3):460–468. doi:10.1097/00007890-200102150-00021. PMID:11233911.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967–1977. doi:10.1056/NEJMoa060068. PMID:17093248.
   PubMed Web of Science ®Google Scholar
• Noel C, Abramowicz D, Durand D, et al. Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol. 2009;20(6):1385–1392. doi:10.1681/ASN.2008101037. PMID:19470677.
   PubMed Web of Science ®Google Scholar
• Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulins. Blood 1998;91(7):2360–2368. PMID:9516135.
   PubMed Web of Science ®Google Scholar
• Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15(5):435–442. PMID:8771497.
   PubMed Web of Science ®Google Scholar
• Hakim FT, Gress RE. Thymic involution: implications for self-tolerance. Methods Mol Biol. 2007;380:377–379. doi:10.1007/978-1-59745-395-0_24. PMID:17876107.
   PubMedGoogle Scholar
• Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844–2853. doi:10.1681/ASN.2006050422. PMID:16914538.
   PubMed Web of Science ®Google Scholar
• Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008;111(7):3675–3683. doi:10.1182/blood-2008-01-130146. PMID:18250226.
   PubMed Web of Science ®Google Scholar
• Liu Z, Fang Y, Wang X, Wang P, Yun P, Xu H. Upregulation of molecules associated with T-regulatory function by thymoglobulin pretreatment of human CD4+ cells. Transplantation 2008;86(10):1419–1426. doi:10.1097/TP.0b013e318187c2e5. PMID:19034013.
   PubMed Web of Science ®Google Scholar
• LaCorcia G, Swistak M, Lawendowski C, et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009;87(7):966–974. doi:10.1097/TP.0b013e31819c84b8. PMID:19352114.
   PubMed Web of Science ®Google Scholar
• Broady R, Yu J, Levings MK. ATG-induced expression of FOXP3 in human CD4(+) T cells in vitro is associated with T-cell activation and not the induction of FOXP3(+) T regulatory cells. Blood 2009;114(24):5003–5006. doi:10.1182/blood-2009-04-214437. PMID:19822903.
   PubMed Web of Science ®Google Scholar
• Noris M, Casiraghi F, Todeschini M, et al. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol. 2007;18:1007–1018. doi:10.1681/ASN.2006101143. PMID:17287424.
   PubMed Web of Science ®Google Scholar
• Gurkan S, Luan Y, Dhillon N, et al. Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant. 2010;10(9):2132–2141. doi:10.1111/j.1600-6143.2010.03210.x. PMID:20883548.
   PubMed Web of Science ®Google Scholar
• Bouvy AP, Klepper M, Kho MM, et al. The impact of induction therapy on the homeostasis and function of regulatory T cells in kidney transplant patients. Nephrol Dial Transplant. 2014;29(8):1587–1597. doi:10.1093/ndt/gfu079. PMID:24771499.
   PubMed Web of Science ®Google Scholar
• Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26(4):186–190. doi:10.1016/j.trim.2012.02.003. PMID:22410573.
   PubMed Web of Science ®Google Scholar
• Todeschini M, Cortinovis M, Perico N, et al. In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol. 2013;191(5):2818–2828. doi:10.4049/jimmunol.1203261. PMID:23913968.
   PubMed Web of Science ®Google Scholar
• Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A, Grande JP. The effect of desensitization protocols on human splenic B-cell populations in vivo. Am J Transplant. 2007;7(2):402–407. doi:10.1111/j.1600-6143.2006.01632.x. PMID:17241113.
   PubMed Web of Science ®Google Scholar
• Elmahdi S, Muramatsu H, Narita A, et al. Correlation of rabbit antithymocyte globulin serum levels and clinical outcomes in children who received hematopoietic stem cell transplantation from an alternative donor. Pediatr Transplant. 2016;20(1):105–113. doi:10.1111/petr.12620. PMID:26518333.
   PubMed Web of Science ®Google Scholar
• Aliabadi AZ, Grommer M, Dunkler D, et al. Impact of rabbit antithymocyte globulin dose on long-term outcomes in heart transplant patients. Transplantation 2016;100(3):685–693. doi:10.1097/TP.0000000000000950. PMID:26457604.
   PubMed Web of Science ®Google Scholar
• Gurk-Turner C, Airee R, Philosophe B, Kukuruga D, Drachenberg C, Haririan A. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation 2008 May 27;85(10):1425–1430. doi:10.1097/TP.0b013e31816dd596.
   PubMed Web of Science ®Google Scholar
• Laftavi MR, Alnimri M, Weber-Shrikant E, et al. Low-dose rabbit antithymocyte globulin versus basiliximab induction therapy in low-risk renal transplant recipients: 8-year follow-up. Transplant Proc. 2011;43(2):458–461. doi:10.1016/j.transproceed.2011.01.035. PMID:21440733.
   PubMed Web of Science ®Google Scholar
• Havenith SH, Remmerswaal EB, Bemelman FJ, et al. Rapid T cell repopulation after rabbit anti-thymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. Clin Exp Immunol. 2012;169(3):292–301. doi:10.1111/j.1365-2249.2012.04622.x. PMID:22861369.
   PubMed Web of Science ®Google Scholar
• Ducloux D, Bamoulid J, Crepin T, et al. Post-transplant immune activation: innocent bystander or insidious culprit of post-transplant accelerated atherosclerosis. Cell Transplant. 2017;26:1601–1609.
   PubMed Web of Science ®Google Scholar
• Luque Y, Jamme M, Rabant M, et al. Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. Nephrol Dial Transplant. 2016;31(3):487–495. doi:10.1093/ndt/gfv362. PMID:26492923.
   PubMed Web of Science ®Google Scholar
• Bamoulid J, Courivaud C, Crepin T, et al. Pretransplant thymic function predicts acute rejection in antithymocyte globulin-treated renal transplant recipients. Kidney Int. 2016;89(5):1136–1143. doi:10.1016/j.kint.2015.12.044. PMID:27083287.
   PubMed Web of Science ®Google Scholar
• Goh BK, Chedid MF, Gloor JM, Raghavaiah S, Stegall MD. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts. Transpl Immunol. 2012;27(2–3):95–100. doi:10.1016/j.trim.2012.07.002. PMID:22813834.
   PubMed Web of Science ®Google Scholar
• Courivaud C, Bamoulid J, Chalopin JM, et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. J Infect Dis. 2013;207(10):1569–1575. doi:10.1093/infdis/jit064. PMID:23417659.
   PubMed Web of Science ®Google Scholar
• Luznik L, Bolanos-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010;115(16):3224–3230. doi:10.1182/blood-2009-11-251595. PMID:20124511.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med. 2011;365(22):2067–2077. doi:10.1056/NEJMoa1105143. PMID:22129253.
   PubMed Web of Science ®Google Scholar
• Ducloux D. Regulatory T cells and cancer: an undesired tolerance. Kidney Int. 2014;86(1):16–18. doi:10.1038/ki.2014.46. PMID:24978377.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Sportes C, Ahmadzadeh M, et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother. 2006;29(3):313–319. doi:10.1097/01.cji.0000210386.55951.c2. PMID:16699374.
   PubMed Web of Science ®Google Scholar
• Chu YW, Memon SA, Sharrow SO, et al. Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function. Blood 2004;104(4):1110–1119. doi:10.1182/blood-2003-10-3635. PMID:15130942.
   PubMed Web of Science ®Google Scholar
• Sportes C, Hakim FT, Memon SA, et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med. 2008;205(7):1701–1714. doi:10.1084/jem.20071681. PMID:18573906.
   PubMed Web of Science ®Google Scholar